EUVIMEDEUVIMED entdecken
Open Access

Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US

Steven D Pearson, Christopher M Whaley, Sarah K Emond

Journal of Comparative Effectiveness Research · 2025

DOI: 10.57264/cer-2025-0083 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2025. Verfasst von Steven D Pearson und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Clinical & Economic Review, Boston, MA 02108, USA. Hauptthemen laut MEDLINE: Obesity, Anti-Obesity Agents, Health Services Accessibility, Health Policy. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-like peptide 1 receptor agonists and glucagon-like peptide 1/gastric inhibitory polypeptide receptor agonists offer weight reduction and associated health benefits that, if sustained over time, have the potential to markedly improve population health. However, over 40% of US adults have obesity, translating into more than 100 million potential new users of obesity medications. Standing in the way of the major opportunity to improve health for these individuals is the massive and likely ongoing cost of treating such a large segment of the population, even though use of the treatments is estimated to be cost–effective over a lifetime. This paper analyzes the range of emerging market approaches and policy reforms that have the potential to help the broader US health system achieve affordable and equitable access to these medications, and the relative advantages, barriers and possible unintended consequences of each approach. We seek to present policymakers and industry leaders with insights and lessons learned from experts while offering a menu of options for the future that will help all stakeholders play an active part in an innovative future of pricing, coverage and payment for new obesity medications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityAnti-Obesity AgentsHealth Services AccessibilityHealth PolicyGlucagon-Like Peptide-1 Receptor AgonistsHumansUnited StatesDrug Costs

Stichwörter der Autor:innen

GLP-1/gastric inhibitory polypeptide (GIP) receptor agonistsaffordable accessbudget impactglucagon-like peptide 1 (GLP-1) receptor agonistsobesity management

Substanzen

Anti-Obesity AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Institute for Clinical & Economic Review, Boston, MA 02108, USA.
  • Brown University, Providence, RI 02912, USA.

Zitieren

APA

Pearson, S. D., Whaley, C. M., & Emond, S. K. (2025). Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2025-0083

Vancouver

Pearson SD, Whaley CM, Emond SK. Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US. Journal of Comparative Effectiveness Research. 2025. doi:10.57264/cer-2025-0083

BibTeX
@article{Pearson2025,
  author = {Pearson, Steven D and Whaley, Christopher M and Emond, Sarah K},
  title = {Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2025},
  doi = {10.57264/cer-2025-0083}
}
Kostenlos starten →